Is there still a room for crizotinib in first-line setting in ALK-positive NSCLC patients?

Cover

Previous Page

28 / 39

Next Page

Information

Previous Page

28 / 39

Next Page

Page Background

What about sequence?

Planchard – Ann Oncol 2018 * Majem – Clin Transl Oncol 2018

SEOM

ESMO

1 … 23 24 25 26 27 28 29 30 31 32 33 34 … 39